ALK-Abelló A/S
AKABY - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.85B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $19.85 Billion |
|---|---|
| Enterprise Value | $18.55 Billion |
| Annual dividend | $0.14 |
| Dividend yield | 0.66% |
| Earnings per Share | $1 |
| Beta | 0.43 |
| Outstanding Shares | 220,571,854 |
Return
| Return on Equity | 19.53% |
|---|---|
| Return on Assets | 13.94% |
| Return on Invested Capital | 22.33% |
Valuation & Multiples
| P/E Ratio | 39.8 |
|---|---|
| PEG | 137.74 |
| Price to Sales | 3.0 |
| Price to Book Ratio | 2.9 |
| Enterprise Value to Revenue | 2.72 |
| Enterprise Value to EBIT | 10.06 |
| Enterprise Value to Net Income | 13 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About ALK-Abelló A/S
2,721 employees
CEO: Peter Halling
Established in 1923 and headquartered in Hørsholm, Denmark, ALK-Abelló A/S is a global pharmaceutical enterprise specializing in allergy treatment. The company provides a comprehensive range of allergy solutions to markets across Europe,...